{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-277083","form_type":"8-K","ticker":null,"cik":"0001445499","company_name":"IMPEL PHARMACEUTICALS INC","filed_at":"2023-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.097550+00:00","generated_at":"2026-06-08T03:22:41.120771+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Impel boosts interim CEO Paolillo salary to $600k, amends change-of-control MIP","bullets":["Len Paolillo appointed interim CEO with base salary increased to $600,000 and increased MIP interest.","CFO Michael Kalb receives one-time $30,000 salary advance, subject to repayment if he leaves before deal close or Dec 31, 2023.","Amended MIP reallocates former CEO Adrian Adams' forfeited 0.85% net consideration interest to remaining participants.","Compensation adjustments permitted via letter agreement with lender Oaktree Fund Administration."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-277083","json":"https://secwatch.observer/filing/0001193125-23-277083.json","markdown":"https://secwatch.observer/filing/0001193125-23-277083.md","text":"https://secwatch.observer/filing/0001193125-23-277083.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1445499/000119312523277083/0001193125-23-277083-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1445499/000119312523277083/d367592d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T03:22:41.120771+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"35f0606ff2","claim":"Leonard S. Paolillo was appointed as interim President and Chief Executive Officer at IMPEL PHARMACEUTICALS INC.","evidence_excerpt":"the Board of Directors (the “ Board ”) of the Company appointed Leonard S. Paolillo, the Company’s Chief Commercial Officer, as interim President and Chief Executive Officer of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1445499/000119312523277083/0001193125-23-277083-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"interim President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"77eb094211","claim":"Adrian Adams resigned as President and Chief Executive Officer at IMPEL PHARMACEUTICALS INC.","evidence_excerpt":"Adrian Adams resigned as chairman of the Board and as President and Chief Executive Officer of Impel Pharmaceuticals Inc.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1445499/000119312523277083/0001193125-23-277083-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}